Today, 2[nd] April 2024, an Extraordinary General Meeting was held in Diagonal Bio AB, reg. no. 559248–8984. Below is a summary of the resolutions passed. All resolutions were passed with the required majority.
Read moreDiagonal Bio AB (publ.) (“Diagonal Bio” or “the Company”) is pleased to announce that the Board of Directors has appointed Karin Wehlin as Chief Executive Officer (CEO) of Diagonal Bio. Karin Wehlin is currently Diagonal Bio’s interim CEO.
Read moreShareholders in Diagonal Bio AB, 559248-8984, are hereby invited to attend an extraordinary general meeting on Tuesday, 2nd of April, 2024, at 13:00 CET at The Spark, conference room 10, Medicon Village, Scheeletorget 1 Lund.
Read moreNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM SWEDISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE. The Board of Directors of Diagonal Bio AB (“Diagonal Bio” or the “Company”) has today, on February 28, 2024, resolved to carry out an issue of units (the “Rights Issue”) consisting of shares and free warrants of series TO 1 (“TO 1”), with preferential right for the Company’s existing shareholders. The decision is subject to approval at the Extraordinary General Meeting scheduled to be held on April 2, 2024. The Rights Issue is conditional upon the limits of the share capital and number of shares in the Articles of Association being amended and the reduction of the share capital being resolved in accordance with the Board of Directors’ proposal to the Extraordinary General Meeting. The issue volume initially amounts to a maximum of approximately SEK 32 million before transaction related costs. Upon full subscription of the Rights Issue and full utilization of issued TO 1 at the highest subscription price, the Company will receive an additional approximately SEK 9.5 million before transaction related costs. The decision on the Rights Issue is secured in writing by members of the Board, management, certain existing owners and external investors to a total of approximately 56.4 percent (corresponding to approximately SEK 18 million) through pre-subscription and guarantee commitments. To finance the operations until the proceeds from the Rights Issue are received by the Company, Diagonal Bio has also raised a bridge loan of approximately SEK 4 million. A prospectus, containing a detailed description of the offer and operations, will be published no later than when the subscription period for the Rights Issue begins. Notice of the Extraordinary General Meeting will be published in a separate press release.
Read more“Looking back at 2023, I am proud to point out the significant steps we have made in our development, including the key achievements such as the CE-marking of LAMPlify® according to Low Voltage Directive (LVD) 2006/95/ EC. A highlight of our fourth quarter was the commencement of LAMPlify® commercialisation.” says, Karin Wehlin, interim CEO Diagonal Bio AB.
Read more
Chair of the Board since 2023
On the board since: 2021
Background and Education: Kerstin Åkesson Jakobsson is a civil engineer with over 30 years of experience in marketing and sales, primarily in the Medtech sector, as well as in corporate management and business development. She has served as CEO for development companies such as SpectraCure AB and Ortoma AB, and CEO for Medicon Village Innovation. Jakobsson has also completed board training at EFL and the Board Academy.
Current Engagements: Senior Advisory of Kongsberg Beam Technology AS and CEO and chairman of Krakesson AB. Board member of the Stiftelsen TEM, QueenInvest AB, and OctaQuest AB.
Holdings in the Company:
Kerstin Jakobsson owns 19,045 shares.
Krakesson AB holds 240,516 shares.
Independent in relation to the Company and its management / major shareholders of the Company: Yes / No
Board Member
On the board since: 2023
Background and Education: Karin Wehlin has an Executive MBA degree from Lunds University and educated at INSEAD in Strategy, Innovation, and Leadership. Karin has over 25 years of experience in senior positions within the Life Science sector. She has served as CEO of Respiratorius AB, LU Food Science AB, and BoMill AB, as well as a Manager in Corporate Finance. Karin is also the founder of EQL Pharma AB, where she was the executive Chairman of the board for 10 years.
Current Engagements: Chair of the Board at Duearity AB and Respiratorius AB.
Holdings in the Company:
0 shares
Independent in relation to the Company and its management / major shareholders of the Company: No / Yes
Board Member
On the board since: 2021
Background and Education: Edvard Hall holds degrees in economics and law and is an entrepreneur with extensive experience in building and managing companies within the sustainability sector. Hall also has a master’s degree in political economy from the London School of Economics.
Current Engagements: CEO of Bioextrax AB (publ), Chairman of the Board for ProLevi Bio AB and Könvyes Invest AB, and Board Member of Parlametric AB.
Holdings in the Company: 358,000 shares and private capital invested in the Company.
Independent in relation to the Company and its management / major shareholders of the Company: Yes / Yes
Board Member
On the board since: 2020
Background and Education: Kushagr Punyani is educated in microfluidics and biosensors. Punyani has co-founded several startups in the tech industry alongside his role as Chief Scientific Officer (CSO) at Spermosens AB, a company specializing in diagnostic equipment and products for male fertility diagnostics and treatment.
Current Engagements: Board member at Spermosens AB, Prolevi Bio AB and Nested Bio AB.
Holdings in the Company:
Kushagr Punyani owns 1,876,000 shares and has private capital invested in the Company.
Nested Bio AB holds 110,292 shares.
Independent in relation to the Company and its management / major shareholders of the Company: Yes / No
Scheelevägen 17
223 63 Lund
Sweden
CEO since November 2023
Board Member since 2023
Learn more about her background and other engagements above.
CFO since 2021
Background and Education: Per Heander holds a degree in Business Administration from Lund University and has 20 years of experience as an Investment Manager in venture capital, with extensive experience in developing young growth companies and serving as a board member. Heander has served as CFO for various companies including Invent Medic, Bomill, and Benchtell AB. He also brings 10 years of experience from different positions within SEB.
Current Engagements: Board member at Gand AB, board member and CEO of Treeridge AB, and deputy board member of Fyra X Invest AB.
Holdings in the Company:
Per Heander owns 104,755 shares, of which 47,615 are through capital insurance.
Treeridge AB holds 473,677 shares.
Karin Wehlin
CEO, Diagonal Bio
Medicon Village, Lund
Phone: +46 770 305 24 88
kw@diagonalbio.com
Svensk Kapitalmarknadsgranskning AB
www.skmg.se
Phone: +46 11 32 30 732
E-mail: ca@skmg.se
Nordic Issuing AB
Stortorget 3
211 22 Malmö
